摘要
目的探讨持续静脉泵注重组人血管内皮抑制素联合化疗一线治疗晚期非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)的随机、对照临床试验。方法选取2019年3月—2022年9月期间雅安市人民医院接受治疗的150例晚期NSCLC患者为研究对象,根据随机数表法划分成两组,每组75例,化疗组给予常规一线化疗方案治疗,联合组在化疗组基础上加以持续静脉泵注重组人血管内皮抑制素治疗,分析两组治疗效果。结果治疗结束后,联合组的总有效率72.00高于化疗组的56.00%,差异有统计学意义(χ^(2)=4.167,P<0.05);联合组血清细胞角蛋白19片段、糖类抗原125、癌胚抗原均低于化疗组,差异有统计学意义(P均<0.05);联合组缺氧诱导因子-1α、血管内皮生长因子及血管生成素2、CD8^(+)均低于化疗组(P均<0.05);联合组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于化疗组,CD8^(+)低于化疗组,差异有统计学意义(P均<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论持续静脉泵注重组人血管内皮抑制素联合化疗一线对晚期NSCLC治疗效果显著,可明显降低患者血清肿瘤标志物和血管内皮因子水平,改善机体免疫功能,以增强对体内肿瘤细胞活性的控制,进而提高临床疗效,且不增加不良反应。
Objective To investigate a randomized,controlled clinical trial of continuous intravenous pumping recom⁃binant human endostatin combined with first-line chemotherapy in the treatment of advanced non-small cell lung can⁃cer(NSCLC).Methods 150 patients with advanced NSCLC treated from March 2019 to September 2022 in Ya'an People's Hospital were selected as the study objects,and divided into two groups according to the random number table method,75 cases in each group,the chemotherapy group was given conventional first-line chemotherapy regi⁃men,and the combination group was treated with continuous intravenous pumps focusing on human vascular endothelial inhibitors on the basis of the chemotherapy group,the effect of treatment between the two groups was analyzed.Results At the end of treatment,the total effective rate of the combination group was 72.00%higher than that of the chemotherapy group(56.00%),and the difference was statistically significant(χ^(2)=4.167,P<0.05).Cytokeratin 19 frag⁃ment,carbohydrate antigen 125 and carcinoembryonic antigen in the combination group,were lower than those of the chemotherapy group,and the differences were statistically significant(all P<0.05);and hypoxia inducible factors-1α,vascular endothelial growth factor and angiopoietin-2,were lower than those of the chemotherapy group in the combi⁃nation group,and the differences were statistically significant(all P<0.05).CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the combination group were higher than thsoe of the chemotherapy group,and CD8^(+)was lower than that of the chemotherapy group,and the differences were statistically significant(all P<0.05);the incidence rate of adverse reactions in the two groups was compared,and the difference was not statistically significant(P>0.05).Conclusion Continuous intravenous pump⁃ing of endostatin combined with first-line chemotherapy is effective in the treatment of advanced NSCLC,which can significantly reduce the levels of serum tumor markers and vascular endothelial factors in patients,improve the im⁃mune function of the body,enhance the control of tumor cell activity in vivo,and thus improve the clinical efficacy without increasing the adverse reactions.
作者
刘涛
唐磊
李青聪
黄东
李自康
LIU Tao;TANG Lei;LI Qingcong;HUANG Dong;LI Zikang(Department of Oncology,Ya'an People's Hospital,Ya'an,Sichuan Province,625000 China)
出处
《系统医学》
2024年第3期33-37,共5页
Systems Medicine
基金
四川省医学科研青年创新课题计划项目(Q19027)。
关键词
持续静脉泵注
重组人血管内皮抑制素
化疗
晚期
非小细胞肺癌
Continuous intravenous pumping
Recombinant human endostatin
Chemotherapy
Late stage
Non small cell lung cancer
